thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
An advertising poster featuring a picture of Michelangelo's David is removed from the Glasgow Subway at the request of the owners of the advertising space because of its nudity. It is replaced with an edited version hiding the crotch region. 20 May – The Annual General Meeting of the General Assembly of the Church of Scotland hears that hundreds of churches may have to close as a result of falling numbers of attendees and income. 21 May – Ten people are injured, and two are taken to hospital, after a bus crashes into a bridge in Glasgow and has its roof torn off. 22 May The Scottish Government offers junior doctors in Scotland a 14.5% pay rise. Margaret Ferrier loses her appeal against a proposed 30 day ban from the House of Commons over her breach of COVID-19 rules in September 2020. 24 May Following a hearing at the High Court in Edinburgh, Rhys Bennett is sentenced to life imprisonment with a minimum of 24 years for the rape and murder of Jill Barclay as she walked home in Aberdeen in September 2022. A group of eight former SNP councillors in North Lanarkshire form a new political party, Progressive Change NL, which becomes North Lanarkshire Council's second largest opposition party. 25 May – Responding to the outcome of a review of Police Scotland, its chief constable, Sir Ian Livingstone, says the force is institutionally sexist, racist and discriminatory.
== Methodology == To begin HPTLC, a stationary phase has to be determined to separate different compounds within a mixture. Around 90% of all pharmaceutical separations are performed on normal phase silica gel; however, other stationary phases such as alumina can be used for samples with dissociating compounds and cellulose for ionic compounds. The reverse-phase HPTLC method (similar methodology to reverse-phase TLC) is used for compounds with high polarity. After the selection of the stationary phase, plates are generally washed with methanol and dried in an oven to remove excess solvent. Selection for the mobile phase is one of the most important processes of HPTLC and follows a 'trial and error' pathway. However, the 'PRISMA' system stands as a guideline for finding the optimal mobile phase. The mobile phase is dependent on the absorptivity of the stationary phase and the composition of the compound of interest. The compound is first tested with solutions such as diethyl ether, ethanol, dichloromethane, chloroform for normal phase HPTLC, or solutions such as methanol, acetonitrile, and tetrahydrofuran for reverse phase HPTLC. The retardation factors (Rf) of the compounds with the selected solvent are then analyzed and the solvent that gives the largest Rf is chosen to be the mobile phase for the compound. Then, the mobile solvent strength is tested against hexane (for normal HPTLC) and water (for reverse-phase HPTLC) to determine the need for adjustment.
was arrested in Dubai on 18 June 2020, due to an international arrest warrant that was sent out by the Belgian courts for his involvement in large scale drug trafficking, but he was eventually released on bail. The majority of the Turtle clan members are currently suspected of hiding out in Dubai and Nador, Morocco. In 2016, a member of the family celebrated his wedding in the Borgerhout district of Antwerp, causing controversy throughout the country as well as on social media. The controversy revolved particularly around the procession that included dozens of luxury cars, which paraded through the lower class district of Borgerhout. According to the Belgian press, the price of these cars was estimated at €7 million. Since 2018, many grenade attacks have occurred in the streets of Antwerp. They are particularly linked to the organisation of the Turtles.
Sources: en.wikipedia.org
=== 2000–2006 === The years from 2000 to 2006 were bloody ones in Colombia with thousands of deaths every year resulting from the ongoing war between the Colombian Armed Forces, Paramilitary groups such as the AUC, and the rebel groups (mainly the FARC, ELN and the EPL). The fighting resulted in massive internal displacement of Colombia's civilian population and thousands of civilian deaths. During President Uribe's first term in office (2002–2006), the security situation inside Colombia showed some measure of improvement, and the economy, while still fragile, showed some positive signs of recovery, according to observers. However, relatively little had been accomplished in structurally solving the country's other grave problems, such as poverty and inequality, possibly in part due to legislative and political conflicts between the administration and the Colombian Congress (including those over a controversial project to eventually give Uribe the possibility of re-election) and a relative lack of freely allocated funds and credits. Some critical observers considered that Uribe's policies, while reducing crime and guerrilla activity, were too slanted in favor of a military solution to Colombia's internal war, while neglecting grave social and human rights concerns. Critics asked for Uribe's government to change this position and make serious efforts towards improving the human rights situation inside the country, protecting civilians, and reducing any abuses committed by the armed forces.
The dragon blood tree has an upturned, densely packed, umbrella-shaped crown. This evergreen species is named after its dark red resin, which is known as "dragon's blood". Unlike most monocot plants, Dracaena displays secondary growth; D. cinnabari even has growth zones resembling tree rings found in dicot tree species. Along with other arborescent Dracaena species it has a distinctive growth habit called "dracoid habitus". Its leaves are found only at the ends of its youngest branches and are shed every three or four years as new leaves simultaneously mature. Branching tends to occur when the growth of the terminal bud is stopped, through either flowering or traumatic events (e.g. herbivory). The tree measures up to 9 m (30 ft) in height and 12 m (39 ft) across the crown, and the trunk reaches up to 1.5 m (4 ft 11 in) DBH. The fruits of D. cinnabari are small fleshy berries containing between one and four seeds. As they develop they turn from green to black, and then become orange when ripe. The berries are eaten by birds (e.g. Onychognatus species) and thereby dispersed. The seeds are 4–5 mm (0.16–0.20 in) in diameter and weigh on average 68 mg. The berries exude a deep red resin colloquially known as dragon's blood. Like other monocotyledons such as palms, the dragon's blood tree grows from the tip of the stem, with the long, stiff leaves borne in dense rosettes at the end. It branches at maturity to produce an umbrella-shaped crown, with leaves that measure up to 60 cm (24 in) long and 3 cm (1.2 in) wide. The trunk and branches of D.
=== Mechanisms === Nicotinic acid reduces synthesis of low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), lipoprotein(a) and triglycerides, and increases high-density lipoprotein cholesterol (HDL-C). The lipid-therapeutic effects of nicotinic acid are partly mediated through the activation of G protein-coupled receptors, including hydroxycarboxylic acid receptor 2 (HCA2)and hydroxycarboxylic acid receptor 3 (HCA3), which are highly expressed in body fat. HCA2 and HCA3 inhibit cyclic adenosine monophosphate (cAMP) production and thus suppress the release of free fatty acids (FFAs) from body fat, reducing their availability to the liver to synthesize the blood-circulating lipids in question. A decrease in free fatty acids also suppresses liver expression of apolipoprotein C3 and PPARg coactivator-1b, thus increasing VLDL-C turnover and reducing its production. Nicotinic acid also directly inhibits the action of diacylglycerol O-acyltransferase 2 (DGAT2) a key enzyme for triglyceride synthesis. The mechanism behind nicotinic acid increasing HDL-C is not totally understood, but seems to occur in various ways. Nicotinic acid increases apolipoprotein A1 levels by inhibiting the breakdown of this protein, which is a component of HDL particles. It also inhibits HDL-C hepatic uptake by suppressing production of the cholesterol ester transfer protein (CETP) gene. It stimulates the ABCA1 transporter in monocytes and macrophages and upregulates peroxisome proliferator-activated receptor gamma, resulting in reverse cholesterol transport.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.